Dysport 500 – Premium Botulinum Toxin Type A for Aesthetic and Neuromuscular Therapy
1. Overview & Manufacturer
Dysport 500 is a botulinum toxin type A product manufactured by Ipsen Biopharm Ltd., a global biopharmaceutical company headquartered in the United Kingdom. Dysport is one of the three major global botulinum toxin brands, alongside Botox® (Allergan) and Xeomin® (Merz), and is widely used in both aesthetic medicine and therapeutic neurology.
The 500-unit formulation is specifically designed for high-dose medical use and for clinics or professionals treating multiple areas in a single session.
2. Composition & Packaging
Each vial of Dysport 500 contains 500 units of Clostridium botulinum toxin type A (abobotulinumtoxinA) in lyophilized powder form
Reconstituted with 0.9% sterile sodium chloride (NaCl) before administration
Contains human serum albumin and lactose as stabilizers
Note: Dysport units are not interchangeable with Botox units (conversion ratio is approximately 2.5–3:1, depending on clinical context)
3. Mechanism of Action
Dysport acts by inhibiting the release of acetylcholine at the neuromuscular junction, thereby blocking the signal from nerve to muscle. This causes:
Temporary muscle relaxation
Reduction of facial expression lines
Improved control of neuromuscular disorders
Suppression of overactive glandular or muscle functions
4. Clinical Advantages
 Fast onset: Dysport may begin to work in as little as 24–48 hours, faster than many competitors
 Proven efficacy in both cosmetic and therapeutic fields for over two decades
 Broader diffusion profile: Useful for treating larger muscle groups or areas such as the forehead
 Long-lasting results, typically 3 to 5 months depending on the treatment and patient response
 Widely used by dermatologists, plastic surgeons, and neurologists worldwide
5. Indications
Aesthetic Use:
Glabellar lines (frown lines)
Horizontal forehead lines
Crow’s feet
Jawline slimming (masseter reduction)
Neck band relaxation (platysmal bands)
Therapeutic Use:
Cervical dystonia
Spasticity in upper or lower limbs (post-stroke, cerebral palsy, etc.)
Blepharospasm and hemifacial spasm
Hyperhidrosis (excessive sweating)
Overactive bladder (off-label in some countries)
6. Safety & Global Certification
Approved by FDA (U.S.), EMA (Europe), and MFDS (Korea) for multiple therapeutic and cosmetic uses
Manufactured in GMP-certified facilities in the UK
Supported by robust clinical trials and long-term safety data
7. Storage & Handling
Store at 2–8°C, protect from light, and do not freeze
Use the reconstituted solution within the manufacturer’s recommended period
Only to be administered by licensed healthcare professionals with training in botulinum toxin applications